PUBLISHER: The Business Research Company | PRODUCT CODE: 1480364
PUBLISHER: The Business Research Company | PRODUCT CODE: 1480364
RNA (ribonucleic acid) targeting small molecule therapeutics are a class of pharmaceutical compounds designed to specifically interact with RNA molecules within cells, modulating their function and activity to treat various diseases. RNA molecules play critical roles in gene expression, protein synthesis and cellular regulation and dysregulation of RNA function is implicated in numerous diseases, including cancer, genetic disorders, viral infections and neurodegenerative diseases.
The RNA targeting small molecule therapeutics market consists of sales of RNA targeting small molecule therapeutics by entities (organizations, sole traders or partnerships) that are engaged in the research, development and commercialization of therapeutic agents designed to interact with RNA through various mechanisms. These offerings include mRNA Translation modulators that affect the process by which messenger RNA (mRNA) is translated into proteins, RNA Splicing modifiers that alter the way in which RNA is spliced and various segments are joined together to form mature mRNA, Direct RNA Targeting molecules that bind directly to RNA to affect its function and other innovative approaches to RNA targeting.
The global RNA targeting small molecules therapeutics market was valued at $1,346.3 million in which grew till 2023 at a compound annual growth rate (CAGR) of more than 28.0%.
Increasing Incidence Of Neurological Disorders
The increasing incidence of neurological disorders propelled the growth of the RNA-targeting small molecule drug discovery market during the historic period. Neurological disorders refer to a wide range of conditions that affect the nervous system, including the brain, spinal cord and nerves, leading to impairments in movement, sensation, cognition, or other neurological functions. The increasing incidence of neurological disorders can be attributed to factors such as aging populations, environmental pollutants, lifestyle changes and improved diagnostic capabilities uncovering previously undetected cases. RNA-targeting small molecule drug discovery aids in addressing neurological disorders by developing therapeutics that specifically target RNA molecules associated with the pathology of these disorders, potentially offering novel treatments to modulate disease progression. According to the National Institutes of Health, a UK-based biomedical research agency, in 2019, neurological diseases comprised 3.8% of the global disease burden and 6.6% of Australia's total disease burden, contrasting with neurological conditions, which accounted for 8% of the burden in 2022. Therefore, the increasing incidence of neurological disorders drove the growth of the RNA targeting small molecule therapeutics market.
Key Players Embrace Startup Solutions In RNA Targeting Small Molecules Therapeutics
Companies in the RNA targeting small molecule therapeutics market are focusing on innovative startup solutions to optimize drug design and enhance RNA-targeted therapeutic development. These solutions facilitate target identification, molecular design and predictive modeling for efficacy and safety to contribute to the health and well-being of all people worldwide. For instance, in February 2024, AION Labs, an Israel-based venture hub for drug discovery and BioMed X, a Germany-based research institute, launched a global call for applications to identify computational biologists, biomedical scientists and inventors to form a new startup at AION Labs. It focuses on the development of an artificial intelligence (AI) and machine learning (ML) computational platform to identify functional regions in RNA that can be targeted with small molecules. RNA has traditionally been deemed unsuitable for small-molecule binding.
The global RNA targeting small molecule therapeutics market is highly concentrated, with a few large players operating in the market. The top ten competitors in the market made up to 98.9% of the total market in 2022.
RNA Targeting Small Molecules Therapeutics Global Market Opportunities And Strategies To 2033 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global RNA targeting small molecules therapeutics market as it emerges from the COVID-19 shut down.
Where is the largest and fastest-growing market for RNA targeting small molecules therapeutics? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The RNA targeting small molecules therapeutics market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider RNA targeting small molecules therapeutics market; and compares it with other markets.